目标新型杂合分子类型为吡唑并[4,3 - e ] -1,2,4-三唑并[1,5- c ]嘧啶膦酸酯4和2-(香豆素-3''-基)-7-苯基吡唑并[4]通过吡唑并三唑并嘧啶氯化物3a–c的Michaelis–Arbuzov重排(Arbuzov反应),磷酸三烷基酯和2-氰基甲基的Knoevenagel反应制备了,3- e -1,2,4-三唑并[1,5- c ]嘧啶5衍生物3d–f分别含有水杨醛。从氨基吡唑1开始,分两步获得前体3。目标化合物4和5通过1 H NMR,13 C NMR,31 P NMR,IR和HRMS完全表征。对化合物4和5的抗乙酰胆碱酯酶活性进行了评估,结果表明它们具有显着的活性(IC 50 = 1.73–39.86 µM),并对这些化合物的初步SAR进行了研究。
Design, synthesis, and structure–activity relationships of indole-3-heterocycles as agonists of the CB1 receptor
作者:Angus J. Morrison、Julia M. Adam、James A. Baker、Robert A. Campbell、John K. Clark、Jean E. Cottney、Maureen Deehan、Anna-Marie Easson、Ruth Fields、Stuart Francis、Fiona Jeremiah、Neil Keddie、Takao Kiyoi、Duncan R. McArthur、Karsten Meyer、Paul D. Ratcliffe、Jurgen Schulz、Grant Wishart、Kazuya Yoshiizumi
DOI:10.1016/j.bmcl.2010.10.093
日期:2011.1
Novel indole-3-heterocycles were designed and synthesized and found to be potent CB1 receptor agonists. Starting from a microsomally unstable lead , a bioisostere approach replacing a piperazine amide was undertaken. This was found to be a good strategy for improving stability both in vitro and in vivo. This led to the discovery of , which had an increased duration of action in the mouse tail flick